COVID-19 antiviral medication no longer available for free in Nova Scotia - Action News
Home WebMail Wednesday, November 13, 2024, 02:27 AM | Calgary | -2.2°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Nova Scotia

COVID-19 antiviral medication no longer available for free in Nova Scotia

Nova Scotia is no longer providing a medication that can lessen the severity of a COVID-19 infection for free. Paxlovid is available at a low cost if you pay for Pharmacare or have a private drug plan, otherwise it'll cost $1,288 to get it.

A normal 5-day course of Paxlovid costs $1,288

A woman with dark hair and glasses sits at a podium.
Michelle Thompson, Nova Scotia's health minister, says that Paxlovid was added this week to the list of drugs covered by the province's Pharmacare programs. (Robert Short/CBC)

A costly drug used to treat people who are at risk of becoming severely ill or dying after contracting COVID-19 is no longer available free of charge in Nova Scotia.

Paxlovid has beenfree foreligible patients inNova Scotia since early 2022, but that has changed now that Ottawa is no longer paying to supply provinces with the antiviral.

Michelle Thompson, Nova Scotia's health minister, said Wednesday the antiviral has been added to the list of drugs covered by the province's Pharmacare programs.

That means those not enrolled in those programs will have to rely on their private health plans to cover the cost or they'll pay out of pocket if they're uninsured.

"There are a number of ways in which people access medications throughout this province," said Thompson. "Andif we see that there is a gap, we will we react to that."

The list price for a five-day course of Paxlovid is $1,288, according to a bulletin for pharmacists from the province.

Paxlovid, made by Pfizer,was approved for use in Canada in 2022. It isused to treat people who are most at risk of a mild to moderate infection becoming serious or life-threatening.

Last month, the expert committee for the Canadian Agency for Drugs and Technologies in Health, the body providing advice for the country's publicly funded health-care systems, offered fresh guidance for how drug plans should cover the treatment.

It suggested Paxlovid should only be reimbursed for patients who are severely or moderatelyimmunosuppressed, or anyone with moderate immunodeficiencies.

Three big Paxlovid pills
Paxlovid is often used to treat people who are at risk of becoming severely ill or dying after contracting COVID-19. (Cory Herperger/CBC Radio-Canada)

Nova Scotians seeking Paxlovid have had to fill out a referral questionnaire, which listsfactors used to determine who qualifies for the drug. They include:

  • Being 65or older.

  • Being moderately or severely immunocompromised.

  • Having one of 12 high-risk factors such as chronic kidney disease, diabetes or cancer.

Thompson said Wednesday only "a very small number of people are eligible for Paxlovid."

Those who will be able to get itthrough Pharmacarewill have to be immunosuppressedeither because of a medical condition, such as an organ transplant, or because they are being treatedfor cancer or other disease.

The Health Department said Nova Scotia received 21,600standard dose treatment courses and 3,700 renal dose treatment courses of Paxlovid through the federally procured supply. It could not say how many doses remain from thatsupply, but the productsareset to expire Friday.

Manitoba, Quebec and British Columbia are continuing to offer Paxlovid free of charge to anyone who meets their criteria.

In B.C.,it's adults who are moderatelyto severely immunocompromised, and/or 60 years oldwith a chronichigh-riskcondition.

In Manitoba, it is available to anyone who is prescribed Paxlovid by their health-care provider.

According to the Quebec Health Department website,anyone eligible for the drug "will be able to receive Paxlovid treatment free of charge at the pharmacy of their choice."

MORE TOP STORIES